OBJECTIVE: To evaluate conditional disease-free survival (CDFS) for patients who underwent curative intent surgery for adrenocortical carcinoma (ACC). BACKGROUND: ACC is a rare but aggressive tumor. Survival estimates are usually reported as survival from the time of surgery. CDFS estimates may be more clinically relevant by accounting for the changing likelihood of disease-free survival (DFS) according to time elapsed after surgery. METHODS: CDFS was assessed using a multi-institutional cohort of patients. Cox proportional hazards models were used to evaluate factors associated with DFS. Three-year CDFS (CDFS3) estimates at "x" year after surgery were calculated as follows: CDFS3 = DFS(x+3)/DFS(x). RESULTS: One hundred ninety-two patients were included in the study cohort; median patient age was 52 years. On presentation, 36% of patients had a functional tumor and median size was 11.5 cm. Most patients underwent R0 resection (75%) and 9% had N1 disease. Overall 1-, 3-, and 5-year DFS was 59%, 34%, and 22%, respectively. Using CDFS estimates, the probability of remaining disease free for an additional 3 years given that the patient had survived without disease at 1, 3, and 5 years, was 43%, 53%, and 70%, respectively. Patients with less favorable prognosis at baseline demonstrated the greatest increase in CDFS3 over time (eg, capsular invasion: 28%-88%, Δ60% vs no capsular invasion: 51%-87%, Δ36%). CONCLUSIONS: DFS estimates for patients with ACC improved dramatically over time, in particular among patients with initial worse prognoses. CDFS estimates may provide more clinically relevant information about the changing likelihood of DFS over time.
OBJECTIVE: To evaluate conditional disease-free survival (CDFS) for patients who underwent curative intent surgery for adrenocortical carcinoma (ACC). BACKGROUND: ACC is a rare but aggressive tumor. Survival estimates are usually reported as survival from the time of surgery. CDFS estimates may be more clinically relevant by accounting for the changing likelihood of disease-free survival (DFS) according to time elapsed after surgery. METHODS:CDFS was assessed using a multi-institutional cohort of patients. Cox proportional hazards models were used to evaluate factors associated with DFS. Three-year CDFS (CDFS3) estimates at "x" year after surgery were calculated as follows: CDFS3 = DFS(x+3)/DFS(x). RESULTS: One hundred ninety-two patients were included in the study cohort; median patient age was 52 years. On presentation, 36% of patients had a functional tumor and median size was 11.5 cm. Most patients underwent R0 resection (75%) and 9% had N1 disease. Overall 1-, 3-, and 5-year DFS was 59%, 34%, and 22%, respectively. Using CDFS estimates, the probability of remaining disease free for an additional 3 years given that the patient had survived without disease at 1, 3, and 5 years, was 43%, 53%, and 70%, respectively. Patients with less favorable prognosis at baseline demonstrated the greatest increase in CDFS3 over time (eg, capsular invasion: 28%-88%, Δ60% vs no capsular invasion: 51%-87%, Δ36%). CONCLUSIONS: DFS estimates for patients with ACC improved dramatically over time, in particular among patients with initial worse prognoses. CDFS estimates may provide more clinically relevant information about the changing likelihood of DFS over time.
Authors: Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas Journal: Gastric Cancer Date: 2007-09-26 Impact factor: 7.370
Authors: Alfredo Berruti; Massimo Terzolo; Paola Sperone; Anna Pia; Silvia Della Casa; David J Gross; Carlo Carnaghi; Paolo Casali; Francesco Porpiglia; Franco Mantero; Giuseppe Reimondo; Alberto Angeli; Luigi Dogliotti Journal: Endocr Relat Cancer Date: 2005-09 Impact factor: 5.678
Authors: D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden Journal: Endocr Relat Cancer Date: 2005-09 Impact factor: 5.678
Authors: Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Shahrokh F Shariat; Claudio Jeldres; Zhe Tian; Jens Hansen; Alberto Briganti; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Eur J Cancer Date: 2011-12-21 Impact factor: 9.162
Authors: M L Kendrick; R Lloyd; L Erickson; D R Farley; C S Grant; G B Thompson; C Rowland; W F Young; J A van Heerden Journal: Arch Surg Date: 2001-05
Authors: J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau Journal: N Engl J Med Date: 1990-04-26 Impact factor: 91.245
Authors: Guillaume Ploussard; Shahrokh F Shariat; Alice Dragomir; Luis A Kluth; Evanguelos Xylinas; Alexandra Masson-Lecomte; Malte Rieken; Michael Rink; Kazumasa Matsumoto; Eiji Kikuchi; Tobias Klatte; Stephen A Boorjian; Yair Lotan; Florian Roghmann; Adrian S Fairey; Yves Fradet; Peter C Black; Ricardo Rendon; Jonathan Izawa; Wassim Kassouf Journal: Eur Urol Date: 2013-10-09 Impact factor: 20.096
Authors: Caroline E Poorman; Lauren M Postlewait; Cecilia G Ethun; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel Journal: Am Surg Date: 2017-07-01 Impact factor: 0.688
Authors: Stefan Buettner; Georgios Antonios Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George A Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2016-08-05 Impact factor: 5.344
Authors: Jon M Gerry; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason A Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides Journal: Ann Surg Oncol Date: 2016-09-02 Impact factor: 5.344
Authors: Natalie A Calcatera; Chi Hsiung-Wang; Nicholas R Suss; David J Winchester; Tricia A Moo-Young; Richard A Prinz Journal: World J Surg Date: 2018-02 Impact factor: 3.352